Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DML8QSZ)

• Drug Name: Amosulalol Drug Info
• Synonyms: Lowgan; LY-137224; YM-09538

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1]

• Cross-matching ID:
  PubChem CID: 2169
  ChEBI ID: CHEBI:135592
  CAS Number: CAS 85320-68-9
  TTD Drug ID: DML8QSZ

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor alpha-2C (ADRA2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[2]
Dihydroergocristine	DM5SQ1G	Alcohol dependence	6C40.2	Approved	[3]
Brimonidine	DMQLT4N	Ocular hypertension	9C61.01	Approved	[4]
Amezinium	DM6I2WQ	Hypotension	BA20-BA21	Approved	[5]
Propylhexedrine	DMTBW2O	Obesity	5B81	Approved	[6]
Tetrahydrozoline	DMT57WC	Ocular disease	1F00.1Z	Approved	[7]
Rilmenidine	DM13PQW	Hypertension	BA00-BA04	Approved	[8]
Xylometazoline	DMKV32D	Allergic rhinitis	CA08.0	Phase 4	[9]
TNX-102	DMO1234	Fibromyalgia	MG30.01	Phase 3	[10]
IDAZOXAN HYDROCHLORIDE	DMSP0X8	Neurological disorder	6B60	Phase 3	[11]

Drug(s) Targeting Adrenergic receptor beta-3 (ADRB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mirabegron	DMS1GYT	Overactive bladder	GC50.0	Approved	[12]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[13]
Bopindolol	DMIFYLX	Hypertension	BA00-BA04	Approved	[14]
Mepindolol	DMUDWP9	Angina pectoris	BA40	Approved	[15]
Rimiterol	DMA47C6	Asthma	CA23	Approved	[16]
Bitolterol	DMK6XAV	Chronic obstructive pulmonary disease	CA22	Approved	[17]
Nipradilol	DMA65ER	Angina pectoris	BA40	Approved	[18]
Vibegron	DMFR201	Overactive bladder	GC50.0	Approved	[19]
ONO-2506	DMCA2PJ	Stroke	8B20	Phase 2/3	[20]
CL-316,243	DMXH1KC	Obesity	5B81	Phase 2	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-2C (ADRA2C)	TT2NUT5	ADA2C_HUMAN	Modulator	[1]
Adrenergic receptor beta-3 (ADRB3)	TTMXGCW	ADRB3_HUMAN	Modulator	[1]

References

• [1] Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
• [2] Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
• [3] Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
• [5] Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
• [6] Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
• [7] Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
• [8] Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
• [9] Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
• [10] Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
• [11] Different sites of action for alpha 2-adrenoceptor antagonists in the modulation of noradrenaline release and contraction response in the vas deferens of the rat. J Pharm Pharmacol. 1992 Mar;44(3):231-4.
• [12] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [13] Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21.
• [14] Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3.
• [15] Pharmacological studies on the intrinsic sympathomimetic activity of the beta-adrenoceptor antagonist mepindolol. Arzneimittelforschung. 1986 May;36(5):811-3.
• [16] Comparison of the beta2-adrenoceptor selectivity of rimiterol, salbutamol and isoprenaline by the intravenous route in man. Br J Clin Pharmacol. 1975 Feb;2(1):41-8.
• [17] Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37.
• [18] Actions of nipradilol (K-351), a new alpha- and beta-adrenoceptor blocker, on the rabbit portal vein. Jpn J Pharmacol. 1984 Aug;35(4):359-69.
• [19] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [20] FR149175, a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Jpn J Pharmacol. 1997 May;74(1):109-12.
• [21] Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des. 2001 Sep;7(14):1433-49.